DXCMDexcom
The financials
Dexcom by the numbers
Dexcom (DXCM) reported revenue of $1.34B in Q3 2026 (quarter ended Sep 30, 2026), up 11% from the same quarter a year earlier. That came with a gross margin of 64% and net income of $275M (20% of revenue). For the full year FY2025, revenue was $4.66B (+16% year on year) and net income $836M. Its largest region in Q2 2026 (quarter ended Jun 30, 2026) was United States at $894M, 81% of the disclosed total, well ahead of Non Us at 19%. The next results filing is expected around Feb 11, 2027, the same week as a year ago.
| Income statement | Q3 2026 | Q3 2025 | Change |
|---|---|---|---|
| Revenue | $1.34B | $1.21B | +11% |
| Gross profit | $864M | $731M | +18% |
| Operating income | $327M | $243M | +35% |
| Net income | $275M | $284M | −3.1% |
| Diluted EPS | $0.72 | $0.70 | +2.9% |
| Geographic | Revenue | Share |
|---|---|---|
| United States | $894M | 81% |
| Non Us | $209M | 19% |
Over its last three fiscal years Dexcom booked income tax of 22.1% of its pretax profit, 18.8% once deferred tax is taken out, close to the 21.3% median for US companies in our tax study.
Business segments
Revenue split by geographic segment, from SEC XBRL filings.
- United States$893.5M$893.5Mvs last quarter +12%vs a year ago +12%+12%+12%
- Non Us$208.9M$208.9Mvs last quarter -2.1%vs a year ago +17%-2.1%+17%
Medical Devices
The closest names by size in the same industry